Medicine and Dentistry
Acute Myeloid Leukemia
11%
Acute Respiratory Distress Syndrome
9%
Adenoma
12%
Adjuvant Therapy
12%
Arm
11%
Artificial Respiration
9%
Asthma
72%
Biological Marker
33%
Biopsy
11%
Body Mass Index
25%
Bone Marrow Transplantation
10%
Breast Cancer
100%
Cancer
9%
Cancer Mortality
14%
Cancer Prevention
15%
Cancer Risk
28%
Cancer Therapy
11%
Cardiovascular Disease
25%
Cardiovascular System
21%
Childbirth
18%
Chronic Obstructive Pulmonary Disease
19%
Cisplatin
13%
Clinical Trial
30%
Clinician
9%
Cohort Analysis
11%
Colon Cancer
13%
Colorectal Adenoma
11%
Colorectal Cancer
27%
COVID-19
20%
Cyclophosphamide
17%
Diabetes
13%
Diagnosis
13%
Diet Therapy
10%
Dietary Pattern
13%
Disease
79%
Disease Free Survival
11%
Doxorubicin
17%
Drug Therapy
11%
Epithelial Cell
9%
Etoposide
10%
Gene Expression
14%
Hazard Ratio
37%
Health Care Cost
9%
Health Disparity
9%
Heart Failure
17%
Heart Failure with Preserved Ejection Fraction
9%
In Vitro
15%
Infection
17%
Integrin
10%
Lung Transplantation
13%
Lymphocyte
8%
Magnetic Resonance Imaging
14%
Malignant Neoplasm
96%
Metabolic Syndrome
9%
Metastatic Breast Cancer
10%
Metastatic Carcinoma
21%
Metastatic Melanoma
10%
Myocardial Infarction
13%
Neoplasm
56%
Nodular Melanoma
31%
Non Small Cell Lung Cancer
21%
Nonalcoholic Fatty Liver
8%
Obesity
11%
Observational Study
9%
Obstructive Sleep Apnea
28%
Odds Ratio
23%
Oncology
44%
Ovarian Cancer
14%
Overall Survival
24%
Pediatrics
17%
Phase II Trials
11%
Physical Activity
37%
Placebo
26%
Positive Airway Pressure
10%
Postmenopause
35%
Prevalence
13%
Proportional Hazards Model
13%
Prostate Cancer
36%
Prostate Carcinoma
17%
Prostate Specific Antigen
10%
Protein P53
9%
Public Health
9%
Quality of Life
17%
Radiation Therapy
25%
Randomized Controlled Trial
15%
Rectum Cancer
10%
Recurrent Disease
16%
Respiratory Disease
13%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Sleep Disorder
13%
Sleep Medicine
10%
Sleep Time
16%
Small Cell Lung Cancer
14%
Surgery
13%
Symptom
32%
Systematic Review
15%
Tamoxifen
9%
Tumor Cell
16%
Wheeze
40%
Women's Health
46%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Infarction
10%
Acute Myeloid Leukemia
9%
Adult Respiratory Distress Syndrome
11%
Adverse Drug Reaction
8%
Adverse Event
10%
Anticarcinogen
10%
Asthma
86%
Bile Acid
9%
Biological Marker
27%
Bone Metastasis
8%
Breast Cancer
74%
Cancer Mortality
8%
Carcinogenesis
7%
Cardiovascular Disease
14%
Chemotherapy
55%
Choline
8%
Chronic Obstructive Lung Disease
17%
Cisplatin
31%
Clinical Trial
30%
Cohort Study
12%
Colon Cancer
14%
Colorectal Adenoma
10%
Colorectal Cancer
16%
Coronavirinae
9%
Cyclophosphamide
41%
Cytotoxicity
11%
Dacarbazine
8%
Denosumab
8%
Disease
94%
Disease Exacerbation
8%
Disease Free Survival
14%
Doxorubicin
38%
Drug Resistance
8%
Dry Powder Inhaler
9%
Effusion
7%
Elimination
9%
Epileptic Absence
7%
Etoposide
16%
Fluorouracil
8%
Fluticasone
7%
Glutathione
8%
Heart Failure
26%
Heart Failure with Preserved Ejection Fraction
18%
Heart Infarction
18%
Imexon
14%
Immunotherapy
12%
Infection
15%
Inflammation
15%
Integrin
8%
Liposome
7%
Lung Cancer
17%
Malignant Neoplasm
63%
Matrilysin
7%
Melanoma
36%
Metastasis
8%
Metastatic Breast Cancer
16%
Metastatic Melanoma
11%
Methionine
9%
Microbiome
9%
Mitomycin
9%
Mouse
54%
Mouse Model
8%
Mycobacterium Bovis BCG
7%
Myeloma
9%
Nanoparticle
11%
Neoplasm
61%
Non Small Cell Lung Cancer
23%
Nonalcoholic Fatty Liver
41%
Obesity
10%
Observational Study
8%
Overall Survival
24%
Paclitaxel
13%
Pancreas Cancer
8%
Pharmacokinetics
24%
Phase II Trials
21%
Placebo
40%
Prevalence
15%
Progression Free Survival
14%
Prostate Cancer
36%
Prostate Carcinoma
18%
Prostate Specific Antigen
12%
Randomized Clinical Trial
8%
Receptor
8%
Recurrent Disease
13%
Remission
17%
Respiratory Tract
8%
SARS Coronavirus
8%
Sleep Disorder
10%
Sleep Disordered Breathing
28%
Small Cell Lung Cancer
17%
Solid Malignant Neoplasm
13%
Spironolactone
9%
Survival Rate
9%
Symptom
30%
Tamoxifen
9%
Tumor Necrosis Factor
9%
Vincristine
9%
Vitamin D
8%
Wheezing
30%
Xenobiotic Agent
10%
Keyphrases
Acute Myocardial Infarction
8%
African American
9%
AIDS/HIV
8%
Allogeneic Bone Marrow Transplantation
9%
Arizona
9%
Asthma
70%
Body Mass Index
22%
Breast Cancer
42%
Breast Cancer Survivors
10%
Cancer Patients
9%
Cancer Survivors
11%
Cardiovascular Disease
11%
Chemotherapy
23%
Childhood Asthma
12%
Chronic Obstructive Pulmonary Disease
8%
Cisplatin
17%
Clinical Trials
16%
Colon Cancer
9%
Colorectal Adenoma
13%
Colorectal Cancer
17%
Confidence Interval
46%
COVID-19
15%
Cyclophosphamide
17%
Cystic Fibrosis
8%
Dietary Intervention
11%
Dietary Modification
9%
Doxorubicin
11%
Early Breast Cancer
10%
Early childhood
8%
Etoposide
9%
Excessive Daytime Sleepiness
9%
First Year of Life
8%
Forced Expiratory Volume in 1 Second (FEV1)
10%
Genome-wide Association Study
10%
Group Studies
23%
Hazard Ratio
28%
Heart Failure
10%
Heart Failure with Preserved Ejection Fraction (HFpEF)
13%
High Risk
8%
Hispanic
15%
Human Prostate
12%
Imexon
14%
Immune Response
8%
In Cancer
16%
Inhaled Corticosteroids
14%
Insomnia
27%
Integrin
10%
Interferon-α (IFN-α)
9%
Liver
12%
Lower Respiratory Tract Infection
12%
Lung
8%
Lung Function
16%
Lung Transplantation
10%
Lymphocytes
14%
Melanoma
17%
Mental Health
9%
Metastasis
8%
Metastatic Breast Cancer
11%
Mouse Model
8%
Non-alcoholic Fatty Liver Disease (NAFLD)
8%
Non-Hispanic White
9%
Non-small Cell Lung Cancer (NSCLC)
10%
Nonalcoholic Steatohepatitis
16%
Obesity
22%
Obstructive Sleep Apnea
18%
Odds Ratio
19%
Older Adults
10%
Overall Survival
10%
Phase II Study
10%
Phase II Trial
16%
Physical Activity
29%
Placebo
15%
Polymorphism
8%
Poor Sleep
8%
Postmenopausal Women
31%
Prostate Cancer
19%
Prostate Carcinoma
9%
Prostate-specific Antigen
8%
Protein Expression
8%
Quality of Life
8%
Randomized Controlled Trial
10%
Randomized Trial
15%
Remission
8%
Response Rate
9%
Risk Factors
22%
Sleep Disorders
12%
Sleep Disturbance
9%
Sleep Duration
19%
Sleep Health
21%
Sleep Quality
10%
Southwest Oncology Group
34%
Tucson
11%
Tumor
21%
Tumor Cells
11%
Tumor Necrosis Factor-α
12%
United States
14%
Weight Control
8%
Weight Loss
10%
Wheezing
32%
Women's Health Initiative
46%